Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with β-thalassaemia major: Application of SQUID biomagnetic liver susceptometry

British Journal of Haematology

Volumn 121, Issue 6, 2003, Pages 938-948

  Fischer, Roland ^a,c   Longo, Filomena ^a   Nielsen, Peter ^d   Engelhardt, Rainer ^d   Hider, Robert C ^b   Piga, Antonio ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^d NONE

Author keywords

Deferiprone; Desferrioxamine; Iron; SQUID; Thalassaemia

Indexed keywords

ALANINE AMINOTRANSFERASE; ASCORBIC ACID; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; FERRITIN; IRON;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; BIOMAGNETISM; BLOOD TRANSFUSION; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; IRON BALANCE; IRON CHELATION; IRON OVERLOAD; LIVER LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SPLEEN; WEIGHT GAIN;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHILD; CHILD, PRESCHOOL; DEFEROXAMINE; HUMANS; IRON; IRON CHELATING AGENTS; LIVER; MAGNETICS; PROSPECTIVE STUDIES; PYRIDONES; TREATMENT OUTCOME;

EID: 0037930751     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04297.x     Document Type: Article

References (50)

1. Agarwal, M.B., Gupte, S.S., Viswanathan, C., Vasandani, D., Ramanathan, J., Desai, N., Puniyani, R.R. & Chhablani, A.T. (1992) Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. British Journal of Haematology, 82, 460-466.
2. Al-Refaie, F.N., Wonke, B., Hoffbrand, A.V., Wickens, D.G., Nortey, P. & Kontoghiorghes, G.J. (1992) Efficacy and possible adverse effects of the oral iron chelator 1,2- dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. Blood, 80, 593-599.
3. Al-Refaie, F.N., De Silva, C.E., Wonke, B. & Hoffbrand, A.V. (1995a) Changes in transferrin saturation after treatment with the oral iron chelator deferiprone in patients with iron overload. Journal of Clinical Pathology, 48, 110-114.
4. Al-Refaie, F.N., Hershko, C., Hoffbrand, A.V., Kosaryan, M., Olivieri, N.F., Tondury, P. & Wonke, B. (1995b) Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. British Journal of Haematology, 91, 224-229.
5. Al-Refaie, F.N., Sheppard, L.N., Nortey, P., Wonke, B. & Hoffbrand, A.V. (1995c) Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. British Journal of Haematology, 89, 403-408.
6. Ambu, R., Crisponi, G., Sciot, R., Van Eyken, P., Parodo, G., Iannelli, S., Marongiu, F., Silvagni, R., Nurchi, V. & Costa, V. (1995) Uneven hepatic iron and phosphorus distribution in beta-thalassemia. Journal of Hepatology, 23, 544-549.
7. Bergeron, R.J., Streiff, R.R., Wiegand, J., Luchetta, G., Creary, E.A. & Peter, H.H. (1992) A comparison of the iron-cleaning properties of 1,2-dimethyl-3- hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine. Blood, 79, 1882-1890.
8. Brittenham, G.M., Cohen, A.R., McLaren, C.E., Martin, M.B., Griffith, P.M., Nienhuis, A.W., Young, N.S., Allen, C.J., Farrell, D.E. & Harris, J.W. (1993) Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thaiassemia major. American Journal of Hematology, 42, 81-85.
9. Brittenham, G.M., Taylor, C.M., Angelucci, E. & Olivieri, N.F. (1998) Long-term evaluation of the efficiency of iron chelation in thalassemia major with balance studies using hepatic iron concentration to determine body iron stores. Blood, 92, 38b.
10. Cohen, A., Martin, M. & Schwartz, E. (1984) Depletion of excessive liver iron stores with desferrioxamine. British Journal of Haematology, 58, 369-373.
11. Cohen, A.R., Galanello, R., Piga, A., Dipalma, A., Vullo, C. & Tricta, F. (2000) Safety profile of the oral iron chelator deferiprone: a multicentre study. British Journal of Haematology, 108, 305-312.
12. Collins, A.F., Fassos, F.F., Stobie, S., Lewis, N., Shaw, D., Fry, M., Templeton, D.M., McClelland, R.A., Koren, G. & Olivieri, N.F. (1994) Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood, 83, 2329-2333.
13. Del Vecchio, G.C., Crollo, E., Schettini, F., Fischer, R. & De Mattia, D. (2000) Factors influencing effectiveness of deferiprone in a thalassaemia major clinical setting. Acta Haematologica, 104, 99-102.
14. Diav-Citrin, O., Atanackovic, G. & Koren, G. (1999) An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major. Therapeutic Drug Monitoring, 21, 74-81.
15. Engelhardt, R., Tiemann, C.D., Janka, G.E., Nielsen, P., Gabbe, E.E. & Fischer, R. (1995) Biomagnetic susceptibility measurements of liver and spleen in thalassemic patients. In: Biomagnetism: Fundamental Research and Clinical Applications (ed. by C. Baumgartner et al), pp. 789-792. Elsevier-IOS, Amsterdam.
16. Fischer, R. (1998) Liver iron susceptometry. In: Magnetism in Medicine - a Handbook (ed. by W. Andrä & H. Nowak), pp. 286-301. Wiley-VCH, Berlin.
17. Fischer, R., Tiemann, C.D., Engelhardt, R., Nielsen, P., Dürken, M., Gabbe, E.E. & Janka, G.E. (1999) Assessment of iron stores in children with transfusion siderosis by biomagnetic liver susceptometry. American Journal of Hematology, 60, 289-299.
18. Gabutti, V. & Piga, A. (1996) Results of long-term iron-chelating therapy. Acta Haematologica, 95, 26-36.
19. Gold, H.J. (1977) Mathematical Modeling of Biological Systems - an Introductory Guidebook. Wiley, New York, pp. 178-185.
20. Grady, R.W., Hilgartner, M.W. & Giardina, P.J. (1996) Deferiprone: its efficacy relative to that of desferal. Blood, 88, 310a.
21. Hershko, C. & Rachmilewitz, E.A. (1978) Iron chelation in thalassemia: mechanism of desferrioxamine action. Israel Journal of Medical Sciences, 14, 1111-1115.
22. Hider, R.C., Kontoghiorghes, G.J. & Silver, J. (1982) UK patent (GB-2118176).
23. Hoffbrand, A.V., Al-Refaie, F., Davis, B., Siritanakatkul, N., Jackson, B.F., Cochrane, J., Prescott, E. & Wonke, B. (1998) Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood, 91, 295-300.
24. Kersten, M.J., Lange, R., Smeets, M.E., Vreugdenhil, G., Roozendaal, K.J., Lameijer, W. & Goudsmit, R. (1996) Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. Annals of Hematology, 73, 247-252.
25. Kontoghiorghes, G.J., Aldouri, M.A., Sheppard, L. & Hoffbrand, A.V. (1987) 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Lancet, 1, 1294-1295.
26. Kontoghiorghes, G.J., Bartlett, A.N., Hoffbrand, A.V., Goddard, J.G., Sheppard, L., Barr, J. & Nortey, P. (1990a) Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). Iron chelation and metabolic studies. British Journal of Haematology, 76, 295-300.
27. Kontoghiorghes, G.J., Goddard, J.G., Bartlett, A.N. & Sheppard, L. (1990b) Pharmacokinetic studies in humans with the oral iron chelator 1,2- dimethyl-3-hydroxypyrid-4-one. Clinical Pharmacology and Therapeutics, 48, 255-261.
28. Leung, N.W., Farrant, P. & Peters, T.J. (1986) Liver Volume measurement by ultrasonography in normal subjects and alcoholic patients. Journal of Hepatology, 2, 157-164.
29. Liu, Z.D., Liu, D.Y., Lu, S.L. & Hider, R. (1999) Synthesis, physicochemical properties and biological evaluation of aromatic ester prodrugs of 1-(2′-hydroxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP102): orally active iron chelators with clinical potential. Journal of Pharmacy and Pharmacology, 51, 555-564.
30. Matsui, D., Klein, J., Hermann, C., Grunau, V., McClelland, R., Chung, D., St-Louis, P., Olivieri, N. & Koren, G. (1991) Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia. Clinical Pharmacology and Therapeutics, 50, 294-298.
31. Mazza, P., Amurri, B., Lazzari, G., Masi, C., Palazzo, G., Spartera, M.A., Giua, R., Sebastio, A.M., Suma, V., De Marco, S., Semeraro, F. & Moscogiuri, R. (1998) Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia. Haematologica, 83, 496-501.
32. Nielsen, P., Fischer, R., Engelhardt, R., Tondury, P., Gabbe, E.E. & Janka, G.E. (1995) Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone. British Journal of Haematology, 91, 827-833.
33. Octave, J.N., Schneider, Y.J., Crichton, R.R. & Trouet, A. (1983) Iron mobilization from cultured hepatocytes: effect of desferrioxamine B. Biochemical Pharmacology, 32, 3413-3418.
34. Olivieri, N.F. & Brittenham, G.M. (1997) Final results of the randomized trial of deferiprone (L1) and deferoxamine (DFO). Blood, 90, 264a.
35. Olivieri, N.F., Koren, G., Hermann, C., Bentur, Y., Chung, D., Klein, J., St Louis, P., Freedman, M.H., McClelland, R.A. & Templeton, D.M. (1990) Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet, 1990, 1275-1279.
36. Olivieri, N.F., Matsui, D., Hermann, C. & Koren, G. (1991) Compliance assessed by the Medication Event Monitoring System. Archives of Disease in Childhood, 66, 1399-1402.
37. Olivieri, N.F., Brittenham, G.M., Matsui, D., Berkovitch, M., Blendis, L.M., Cameron, R.G., McClelland, R.A., Liu, P.P., Templeton, D.M. & Koren, G. (1995) Iron-chelation therapy with oral deferipronein patients with thalassemia major. New England Journal of Medicine, 332, 918-922.
38. Olivieri, N.F., Brittenham, G.M., McLaren, C.E., Templeton, D.M., Cameron, R.G., McClelland, R.A., Burt, A.D. & Fleming, K.A. (1998) Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. New England Journal of Medicine, 339, 417-423.
39. Paulson, D.N., Fagaly, R.L., Toussaint, R.M. & Fischer, R. (1991) Biomagnetic susceptometer with SQUID instrumentation. IEEE Transactions on Magnetism, MAG-27, 3249-3252.
40. Piga, A., Facello, S., Gaglioti, C., Pucci, A., Pietribiasi, F. & Zimmermann, A. (1998) No progression of liver fibrosis in thalassemia major during deferiprone or desferrioxamine iron chelation. Blood, 92, 3065.
41. Pippard, M.J. & Weatherall, D.J. (2000) Oral iron chelation therapy for thalassaemia: an uncertain scene. British Journal of Haematology, 111, 2-5.
42. Porter, J.B. (2001) Practical management of iron overload. British Journal of Haematology, 115, 239-252.
43. Porter, J.B., Huehns, E.R. & Hider, R.C. (1989a) The development of iron chelating drugs. Bailliere's Best Practice and Research. Clinical Haematology, 2, 257-292.
44. Porter, J.B., Jaswon, M.S., Huehns, E.R., East, C.A. & Hazell, J.W. (1989b) Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. British Journal of Haematology, 73, 403-409.
45. Stella, M., Pinzello, G. & Maggio, A. (1998) Iron chelation with oral deferiprone in patients with thalassemia. New England Journal of Medicine, 339, 1712-1714.
46. Taher, A., Chamoun, F.M., Koussa, S., Saad, M.A., Khoriaty, A.I., Neeman, R. & Mourad, F.H. (1999) Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine. Acta Haematologica, 101, 173-177.
47. Taher, A., Sheikh-Taha, M., Koussa, S., Inati, A., Neeman, R. & Mourad, F. (2001) Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients. European Journal of Haematology, 67, 30-34.
48. Thalassemia International Federation (TIF) (2000) Guidelines for Clinical Management of Thalassemia (ed. by N. Cappellini et al.). TIF, Nicosia, Cyprus.
49. Töndury, P., Kontoghiorghes, G.J., Ridolfi-Luthy, A., Hirt, A., Hoffbrand, A.V., Lottenbach, A.M., Sonderegger, T. & Wagner, H.P. (1990) L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major. British Journal of Haematology, 76, 550-553.
50. Töndury, P., Zimmermann, A., Nielsen, P. & Hirt, A. (1998) Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. British Journal of Haematology, 101, 413-415.